Gilead Sciences - 31 Year Stock Price History | GILD

Historical daily share price chart and data for Gilead Sciences since 1992 adjusted for splits. The latest closing stock price for Gilead Sciences as of February 03, 2023 is 84.50.
  • The all-time high Gilead Sciences stock closing price was 94.64 on June 23, 2015.
  • The Gilead Sciences 52-week high stock price is 89.74, which is 6.2% above the current share price.
  • The Gilead Sciences 52-week low stock price is 57.16, which is 32.4% below the current share price.
  • The average Gilead Sciences stock price for the last 52 weeks is 68.42.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Gilead Sciences Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2023 84.6900 85.3900 88.0800 81.3900 84.5000 -1.57%
2022 65.5461 69.4286 88.7372 55.4052 85.8500 23.60%
2021 63.2453 55.1419 70.4426 55.0410 69.4573 29.96%
2020 61.6163 57.4547 74.7209 51.9678 53.4448 -6.62%
2019 56.6198 53.8075 59.9766 52.9861 57.2345 7.88%
2018 61.4537 60.9176 73.0025 51.3478 53.0526 -9.92%
2017 58.5313 59.2312 69.3387 51.6053 58.8953 2.97%
2016 65.8266 76.5272 80.2487 56.9567 57.1946 -27.61%
2015 82.4854 73.2342 94.6440 73.2342 79.0102 8.63%
2014 69.1205 58.0334 88.1342 50.5255 72.7327 25.51%
2013 43.2573 28.9588 58.0257 28.9164 57.9485 104.49%
2012 21.8063 16.1500 29.4526 16.1500 28.3377 79.45%
2011 15.4045 14.1129 16.6708 13.6345 15.7912 12.94%
2010 15.1509 16.7055 19.0782 12.2803 13.9817 -16.25%
2009 17.7917 20.1315 20.3707 15.9879 16.6939 -15.39%
2008 18.9758 17.4926 22.0297 14.4563 19.7303 11.15%
2007 15.2703 12.1819 18.4185 12.1009 17.7511 41.72%
2006 11.9428 10.5519 13.4551 10.3686 12.5253 23.51%
2005 8.1551 6.6996 10.7313 5.9878 10.1410 50.24%
2004 6.2065 5.5962 7.5310 4.9924 6.7497 20.08%
2003 4.9661 3.3652 6.7507 3.1154 5.6212 71.41%
2002 3.2847 2.9625 3.8301 2.5608 3.2794 3.47%
2001 2.4182 1.7875 3.4824 1.3036 3.1694 58.48%
2000 1.8167 1.3578 2.8019 1.0475 1.9999 53.23%
1999 1.2872 0.9585 2.2276 0.8620 1.3052 31.83%
1998 0.7691 0.9194 1.0429 0.4401 0.9901 7.35%
1997 0.7560 0.5908 1.1123 0.5216 0.9223 53.00%
1996 0.6838 0.7866 0.9826 0.4160 0.6028 -21.88%
1995 0.4445 0.2261 0.7776 0.2261 0.7716 236.80%
1994 0.2425 0.2894 0.3376 0.1688 0.2291 -20.84%
1993 0.3567 0.4401 0.4613 0.2592 0.2894 -37.66%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $105.984B $27.281B
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00